Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG) Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01174862|
Recruitment Status : Completed
First Posted : August 4, 2010
Last Update Posted : March 10, 2015
In patients undergoing coronary artery bypass graft (CAGB) surgery, aspirin is commonly prescribed to prevent graft thrombosis and myocardial ischemia. However, there are still a significant number of grafts occluding in the postoperative period. This is partly attributed to reduced aspirin responsiveness, also called "aspirin resistance". At the moment, no standardized definition or laboratory test is available to quantify "aspirin resistance", and strong platelet reactivity in laboratory tests is not necessarily associated with increased thrombotic events. However, there is increasing evidence that reduced aspirin responsiveness in platelet function analyzers is associated with adverse long-term outcome and higher incidence of major adverse events in patients with stable coronary artery disease and in patients undergoing percutaneous coronary intervention. In patients undergoing coronary artery bypass graft surgery, the predictive value of a laboratory finding of reduced aspirin responsiveness remains unclear.
Therefore, the aim of this study is to prospectively evaluate whether the pre- and/or postoperative laboratory finding of reduced aspirin responsiveness defined by MultiplateTM platelet function analyzer is associated with higher incidences of adverse outcome after 30 days and 12 months in patients undergoing CABG surgery.
|Condition or disease|
|Coronary Artery Bypass Graft Triple Vessel Myocardial Ischemia Thrombosis Antithrombotic Drugs [Platelet-aggregation Inhibitors] Causing Adverse Effects in Therapeutic Use|
|Study Type :||Observational|
|Actual Enrollment :||304 participants|
|Official Title:||Comparative Cohort Study on the Outcome of Patients With Normal and Reduced Acetylsalicylic Acid Responsiveness Undergoing Coronary Artery Bypass Surgery|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2013|
Normal aspirin responsiveness in ASPI test (Multiplate)
Reduced aspirin responsiveness in ASPI test (Multiplate)
- Death and/or major cardiac or thromboembolic events [ Time Frame: 12 months after cardiac surgery ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01174862
|Department of Anaesthesia and Intensive Care Unit, Univeristy Hospital Basel, Switzerland|
|Basel, Basel-Stadt, Switzerland, 4031|
|Principal Investigator:||Daniel Bolliger, MD||Department of Anaesthesia and Intensive Care Unit, University Hospital Basel, Switzerland|